Navigation Links
Lorus Therapeutics Announces Scientific Presentations for Lead,Antisense and siRNA Drug Candidates at International Cancer,Conference

tes that can be used, either alone, or in combination with other drugs, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Lorus has several product candidates in multiple Phase II clinical trials and has completed one Phase II and one Phase III clinical trial. Lorus Therapeutics Inc. is listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP.

Forward looking statements

This press release may contain forward-looking statements within the meaning of Canadian and U.S. securities laws. Such statements include, but are not limited to, statements relating to: our research program plans, our plans to conduct clinical trials, the successful and timely completion of clinical studies and the regulatory approval process, our ability to fund future research, our plans to obtain partners to assist in the further development of our product candidates, the establishment of corporate alliances, the Company's plans, objectives, expectations and intentions and other statements including words such as "continue", "believe", "plan", "expect", "intend", "will", "should", "may", and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements, including, among others: our ability to obtain the capital required for research and operations, the inherent risks in early stag
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:10/17/2014)... , Oct. 17, 2014  Talyst, a market ... 2014 LeadingAge Annual Meeting in Nashville, TN. ... System, the market leading solution for onsite, remote medication ... term care facilities to safely and securely dispense medication ... to first dose, helps ensure that the correct medication ...
(Date:10/17/2014)... , Oct. 17, 2014  Ameritox SM , ... the appointment of Thomas Smith , M.D., as ... a field-based team offering scientific resources for healthcare providers, ... has held leadership positions at a variety of healthcare ... benefit both the pain and behavioral health sides of ...
(Date:10/17/2014)... 2014   DaVita HealthCare Partners Inc. ... nation,s largest and most innovative health care communities, ... the company,s award-winning, leadership development and cultural orientation ... from around the globe were in attendance for ... is a two-day one-of-a-kind experience for new and ...
Breaking Medicine Technology:Talyst Exhibits at LeadingAge Annual Meeting 2Ameritox Appoints New Chief Medical Officer 2DaVita HealthCare Partners Celebrates New-Teammate Training and Leadership Milestone 2DaVita HealthCare Partners Celebrates New-Teammate Training and Leadership Milestone 3
... Naurex Inc., a clinical-stage company developing innovative ... today announced that it has initiated a Phase II ... Glycine-site Functional Partial Agonist (GFPA) selective modulator of the ... therapy for patients who are not achieving an adequate ...
... 2011 Cempra Pharmaceuticals Inc. today announced that ... present at the 2011 Wells Fargo Healthcare Conference at ... Fernandes will provide an overview of the company,s two ... and other infections and TAKSTA™ for the oral treatment ...
Cached Medicine Technology:Naurex Initiates Phase II Clinical Trial of Novel Antidepressant GLYX-13 in Treatment-Resistant Depression 2Naurex Initiates Phase II Clinical Trial of Novel Antidepressant GLYX-13 in Treatment-Resistant Depression 3
(Date:10/20/2014)... New York, NY (PRWEB) October 20, 2014 ... to be introduced in the U.S., has a lot to ... time when our country recognizes the achievements and contributions of ... marks the anniversary for Punzoné, and today it shares its ... and take a trip to Italy - even if it ...
(Date:10/20/2014)... Maryland, USA (PRWEB) October 20, 2014 ... to track interventions? Here comes a wonderful app Metassessor ... mobile app development company helped its client “Intervention ... more efficiently. The app is designed for iOS 4.3 ... iPod touch. This app is optimized for iPhone 5. ...
(Date:10/19/2014)... October 20, 2014 The leading ... ( http://www.top10bestseohosting.com/go/iPage/ ) and GreenGeeks are the best ... platforms for those who want to buy high ... time. , The IT manager of Top10BestSEOHosting.com says, ... most recommended suppliers for everyone. A lot of ...
(Date:10/19/2014)... 19, 2014 Dr. Babatunde Osotimehin, Executive ... news of a ceasefire agreement that is expected to ... girls who were kidnapped from the north-eastern Nigerian town ... captivity long enough, and it is high time they ... Dr. Osotimehin. , "We owe it to these girls ...
(Date:10/19/2014)... Having been working in the garment industry for decades, ... According to James, one of the company’s top designers, many ... high-low skirts that add beauty to them. Chiffon floor length ... unveiled its new selection of 2014 long prom dresses. ... items are available in over 20 popular designs. The company ...
Breaking Medicine News(10 mins):Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 4Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2Health News:2014 Long Prom Dresses From LunaDress Now Available In Over 20 Popular Designs 2
... Rochelle, NY -- The current issue of Medical ... Liebert, Inc., explores how the U.S. military is incorporating ... military personnel serving in the war zones and the ... issue is available online at http://www.liebertpub.com/acu . ...
... 4, 2012 As the pharmaceutical industry continues to ... protecting patients from counterfeit medicines, as well as the ... mounted. In an effort to encourage comprehensive public standards ... is proposing a set of recommended best practices that ...
... used extensively in Chinese traditional medicine that kill ... the leading causes of tooth loss in children and adults. ... , they say that these substances could have a role ... Stefan Gafner and colleagues explain that the dried root ...
... Weight loss surgery is not a cure for type 2 ... a new study published in the British Journal of ... to 80 per cent of diabetes patients have been cured ... that only 41 per cent of patients achieve remission using ...
... -- Arrogant people are less likely than humble people to ... Although personal factors (such as previous time commitments and ... how many people are watching) come into play, humility is ... helping hand, according to the study published online Jan. 2 ...
... a study that investigates the challenges of disseminating clinical research ... have found that fewer than half of a sample of ... Health (NIH) were published within 30 months of completing the ... issue of the British Medical Journal , which focuses ...
Cached Medicine News:Health News:Proposed standard offers best practices to help ensure pharmaceutical supply chain integrity 2Health News:Proposed standard offers best practices to help ensure pharmaceutical supply chain integrity 3Health News:Proposed standard offers best practices to help ensure pharmaceutical supply chain integrity 4Health News:Scientists reassess weight loss surgery for type 2 diabetes 2Health News:Need Help? Seek Out the Humble 2Health News:Many NIH-funded clinical trials go unpublished over 2 years after completion 2
Gentamicin is an aminoglycosidic antibiotic that inhibits bacterial growth by inhibiting protein synthesis. Gentamicin is used for prevention and elimination of bacterial contaminants in cell culture...
LB Agar plates with 10mM Magnesium Sulfate....
LB Agar plates with 0.1mM EDTA....
1% tryptone, 0.5% yeast extract, 1.0% Sodium Chloride. 1.5% agararose...
Medicine Products: